Comparison of 3-year clinical outcomes between resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis

Eui Im, Byeong Keuk Kim, Young Guk Ko, Ae Young Her, Hyun Hee Choi, Dong Ho Shin, Jung Sun Kim, Donghoon Choi, Yangsoo Jang, Myeongki Hong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives Long-term clinical outcomes were evaluated in long coronary artery stenosis treated with different types of drug-eluting stents. Background Long-term follow-up data to compare clinical outcomes between Resolute™ zotarolimus-eluting stent (R-ZES) versus sirolimus-eluting stent (SES) implantation for long coronary artery stenosis is insufficient. Methods A total of 254 patients (307 lesions) treated with R-ZES and 265 patients (303 lesions) treated with SES for long coronary lesions (total stent length ≥30 mm) were enrolled, and long-term (3 years) clinical outcomes were compared between the 2 groups. Efficacy (target lesion revascularization [TLR]) and safety (the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis) were assessed. Results The 2 groups had similar baseline characteristics except for the duration of dual antiplatelet therapy (23.4 ± 11.2 months in R-ZES-treated patients vs. 27.4 ± 13.9 months in SES-treated patients, P < 0.001). Total stent length was similar in R-ZES-treated patients (45.0 ± 19.0 mm) and SES-treated patients (45.4 ± 18.6 mm) (P = 0.464). The cumulative TLR rate was 4.6% in R-ZES-treated patients versus 4.6% in SES-treated patients (P = 0.911). For safety parameters, R-ZES-treated patients showed a significantly lower rate of the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis than SES-treated patients (0.4% vs. 2.4%, P = 0.042). Particularly, the occurrence of target lesion-related definite stent thrombosis was significantly lower in R-ZES-treated patients than in SES-treated patients (0.0% vs. 2.0%, P = 0.028). Conclusions R-ZES stents showed superior long-term safety than SES for treating long coronary lesions, while maintaining a similar clinical efficacy.

Original languageEnglish
Pages (from-to)378-383
Number of pages6
JournalJournal of Interventional Cardiology
Volume26
Issue number4
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Coronary Stenosis
Sirolimus
Stents
zotarolimus
Thrombosis
Safety
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Im, Eui ; Kim, Byeong Keuk ; Ko, Young Guk ; Her, Ae Young ; Choi, Hyun Hee ; Shin, Dong Ho ; Kim, Jung Sun ; Choi, Donghoon ; Jang, Yangsoo ; Hong, Myeongki. / Comparison of 3-year clinical outcomes between resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis. In: Journal of Interventional Cardiology. 2013 ; Vol. 26, No. 4. pp. 378-383.
@article{4355ba7999f14679b322d325e59b2f77,
title = "Comparison of 3-year clinical outcomes between resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis",
abstract = "Objectives Long-term clinical outcomes were evaluated in long coronary artery stenosis treated with different types of drug-eluting stents. Background Long-term follow-up data to compare clinical outcomes between Resolute™ zotarolimus-eluting stent (R-ZES) versus sirolimus-eluting stent (SES) implantation for long coronary artery stenosis is insufficient. Methods A total of 254 patients (307 lesions) treated with R-ZES and 265 patients (303 lesions) treated with SES for long coronary lesions (total stent length ≥30 mm) were enrolled, and long-term (3 years) clinical outcomes were compared between the 2 groups. Efficacy (target lesion revascularization [TLR]) and safety (the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis) were assessed. Results The 2 groups had similar baseline characteristics except for the duration of dual antiplatelet therapy (23.4 ± 11.2 months in R-ZES-treated patients vs. 27.4 ± 13.9 months in SES-treated patients, P < 0.001). Total stent length was similar in R-ZES-treated patients (45.0 ± 19.0 mm) and SES-treated patients (45.4 ± 18.6 mm) (P = 0.464). The cumulative TLR rate was 4.6{\%} in R-ZES-treated patients versus 4.6{\%} in SES-treated patients (P = 0.911). For safety parameters, R-ZES-treated patients showed a significantly lower rate of the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis than SES-treated patients (0.4{\%} vs. 2.4{\%}, P = 0.042). Particularly, the occurrence of target lesion-related definite stent thrombosis was significantly lower in R-ZES-treated patients than in SES-treated patients (0.0{\%} vs. 2.0{\%}, P = 0.028). Conclusions R-ZES stents showed superior long-term safety than SES for treating long coronary lesions, while maintaining a similar clinical efficacy.",
author = "Eui Im and Kim, {Byeong Keuk} and Ko, {Young Guk} and Her, {Ae Young} and Choi, {Hyun Hee} and Shin, {Dong Ho} and Kim, {Jung Sun} and Donghoon Choi and Yangsoo Jang and Myeongki Hong",
year = "2013",
month = "8",
day = "1",
doi = "10.1111/joic.12047",
language = "English",
volume = "26",
pages = "378--383",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "4",

}

Comparison of 3-year clinical outcomes between resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis. / Im, Eui; Kim, Byeong Keuk; Ko, Young Guk; Her, Ae Young; Choi, Hyun Hee; Shin, Dong Ho; Kim, Jung Sun; Choi, Donghoon; Jang, Yangsoo; Hong, Myeongki.

In: Journal of Interventional Cardiology, Vol. 26, No. 4, 01.08.2013, p. 378-383.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of 3-year clinical outcomes between resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis

AU - Im, Eui

AU - Kim, Byeong Keuk

AU - Ko, Young Guk

AU - Her, Ae Young

AU - Choi, Hyun Hee

AU - Shin, Dong Ho

AU - Kim, Jung Sun

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Hong, Myeongki

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Objectives Long-term clinical outcomes were evaluated in long coronary artery stenosis treated with different types of drug-eluting stents. Background Long-term follow-up data to compare clinical outcomes between Resolute™ zotarolimus-eluting stent (R-ZES) versus sirolimus-eluting stent (SES) implantation for long coronary artery stenosis is insufficient. Methods A total of 254 patients (307 lesions) treated with R-ZES and 265 patients (303 lesions) treated with SES for long coronary lesions (total stent length ≥30 mm) were enrolled, and long-term (3 years) clinical outcomes were compared between the 2 groups. Efficacy (target lesion revascularization [TLR]) and safety (the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis) were assessed. Results The 2 groups had similar baseline characteristics except for the duration of dual antiplatelet therapy (23.4 ± 11.2 months in R-ZES-treated patients vs. 27.4 ± 13.9 months in SES-treated patients, P < 0.001). Total stent length was similar in R-ZES-treated patients (45.0 ± 19.0 mm) and SES-treated patients (45.4 ± 18.6 mm) (P = 0.464). The cumulative TLR rate was 4.6% in R-ZES-treated patients versus 4.6% in SES-treated patients (P = 0.911). For safety parameters, R-ZES-treated patients showed a significantly lower rate of the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis than SES-treated patients (0.4% vs. 2.4%, P = 0.042). Particularly, the occurrence of target lesion-related definite stent thrombosis was significantly lower in R-ZES-treated patients than in SES-treated patients (0.0% vs. 2.0%, P = 0.028). Conclusions R-ZES stents showed superior long-term safety than SES for treating long coronary lesions, while maintaining a similar clinical efficacy.

AB - Objectives Long-term clinical outcomes were evaluated in long coronary artery stenosis treated with different types of drug-eluting stents. Background Long-term follow-up data to compare clinical outcomes between Resolute™ zotarolimus-eluting stent (R-ZES) versus sirolimus-eluting stent (SES) implantation for long coronary artery stenosis is insufficient. Methods A total of 254 patients (307 lesions) treated with R-ZES and 265 patients (303 lesions) treated with SES for long coronary lesions (total stent length ≥30 mm) were enrolled, and long-term (3 years) clinical outcomes were compared between the 2 groups. Efficacy (target lesion revascularization [TLR]) and safety (the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis) were assessed. Results The 2 groups had similar baseline characteristics except for the duration of dual antiplatelet therapy (23.4 ± 11.2 months in R-ZES-treated patients vs. 27.4 ± 13.9 months in SES-treated patients, P < 0.001). Total stent length was similar in R-ZES-treated patients (45.0 ± 19.0 mm) and SES-treated patients (45.4 ± 18.6 mm) (P = 0.464). The cumulative TLR rate was 4.6% in R-ZES-treated patients versus 4.6% in SES-treated patients (P = 0.911). For safety parameters, R-ZES-treated patients showed a significantly lower rate of the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis than SES-treated patients (0.4% vs. 2.4%, P = 0.042). Particularly, the occurrence of target lesion-related definite stent thrombosis was significantly lower in R-ZES-treated patients than in SES-treated patients (0.0% vs. 2.0%, P = 0.028). Conclusions R-ZES stents showed superior long-term safety than SES for treating long coronary lesions, while maintaining a similar clinical efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84882236032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882236032&partnerID=8YFLogxK

U2 - 10.1111/joic.12047

DO - 10.1111/joic.12047

M3 - Article

C2 - 23844852

AN - SCOPUS:84882236032

VL - 26

SP - 378

EP - 383

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 4

ER -